An animated explainer on sermorelin asks whether the peptide lives up to anti-aging talk. Treat any health claims as unproven until backed by trials.
Recap by typeshit. Full story at The Infographics Show.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
An Epic records analysis presented at the ophthalmology academy meeting found the drop only after adjusting for other conditions. Unadjusted data had pointed to 68% higher odds.
A generic Facebook post aimed at people on Ozempic, Wegovy, Zepbound or Mounjaro, teasing an overlooked side of treatment without saying what it is.
Loading…